Nuwellis Showcases New Research at International Heart and Lung Transplantation Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Should l Buy NUWE?
Source: Newsfilter
- Research Presentation: At the 2026 International Society for Heart and Lung Transplantation meeting, the University of Iowa showcased a case study on using ultrafiltration to treat pediatric heart failure, emphasizing its significance in managing complex pediatric cardiorenal patients, which may drive standardization in clinical practice.
- Clinical Application Potential: The case study demonstrated that Aquadex ultrafiltration therapy effectively managed fluid overload in patients with chemotherapy-induced dilated cardiomyopathy, improving pre-operative clinical status and enhancing post-transplant outcomes, indicating its potential in pediatric settings.
- Technology Promotion Strategy: Nuwellis CEO John Erb stated that the company will continue collaborating with practitioners to promote the adoption of Aquadex for pediatric indications, addressing fluid management challenges and enhancing patient care quality.
- Industry Exchange Platform: The ISHLT conference provided a vital opportunity for clinicians and researchers to share emerging data and engage in scientific dialogue, with Nuwellis' participation further solidifying its leadership position in heart and lung disease treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUWE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUWE
Wall Street analysts forecast NUWE stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 1.100
Low
5.50
Averages
5.50
High
5.50
Current: 1.100
Low
5.50
Averages
5.50
High
5.50
About NUWE
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nuwellis Showcases New Research at International Heart and Lung Transplantation Conference
- Research Presentation: At the 2026 International Society for Heart and Lung Transplantation meeting, the University of Iowa showcased a case study on using ultrafiltration to treat pediatric heart failure, emphasizing its significance in managing complex pediatric cardiorenal patients, which may drive standardization in clinical practice.
- Clinical Application Potential: The case study demonstrated that Aquadex ultrafiltration therapy effectively managed fluid overload in patients with chemotherapy-induced dilated cardiomyopathy, improving pre-operative clinical status and enhancing post-transplant outcomes, indicating its potential in pediatric settings.
- Technology Promotion Strategy: Nuwellis CEO John Erb stated that the company will continue collaborating with practitioners to promote the adoption of Aquadex for pediatric indications, addressing fluid management challenges and enhancing patient care quality.
- Industry Exchange Platform: The ISHLT conference provided a vital opportunity for clinicians and researchers to share emerging data and engage in scientific dialogue, with Nuwellis' participation further solidifying its leadership position in heart and lung disease treatment.
See More
Nuwellis Receives Patent Allowance for Dual-Lumen Catheter
- Patent Progress: Nuwellis announced it received a Notice of Allowance from the USPTO for its dual-lumen catheter used in ultrafiltration therapy, aimed at improving blood flow and reducing treatment complications, which is expected to enhance its product lineup.
- Enhanced Design Flexibility: The catheter features an adjustable, flexible design that allows doctors to customize it during treatment, ensuring smoother usage and improved treatment outcomes across various patients.
- Market Expansion Potential: Once the patent is officially approved, it is anticipated to support Nuwellis in promoting ultrafiltration therapy in hospitals and outpatient settings, thereby expanding market share and enhancing competitive positioning.
- Stock Price Reaction: Despite the positive patent news, Nuwellis' stock is trading approximately 3% lower at around $1.13, reflecting market caution regarding its future growth potential.
See More
Nuwellis Announces Aquadex Software Update for Enhanced Clinical Workflow
- Software Update Enhancement: Nuwellis' release of the Aquadex SmartFlow® software update reduces ultrafiltration adjustment step size from 10 mL/hr to 5 mL/hr, which is particularly crucial in pediatric care, significantly improving clinical outcomes related to small-volume fluid shifts and enhancing patient safety and treatment efficacy.
- User Experience Optimization: The update aims to streamline clinical workflows and enhance device usability, especially providing better therapy visibility for nursing staff, which is expected to improve nursing efficiency and reduce operational errors, thereby elevating overall care quality.
- Key Algorithm Improvements: The update includes a refined blood flow algorithm designed to reduce nuisance alarms and improve flow stability, which will help clinicians detect potential filter clotting earlier, thus increasing the safety and effectiveness of treatments.
- No-Cost Update: This software update is available at no cost to existing customers and can be deployed through standard update processes, with support from Nuwellis' field and service teams ensuring a smooth transition to the new system, further solidifying customer relationships.
See More
Nuwellis Welcomes Back Three Key Team Members
- Team Restructuring: Nuwellis announces the return of three former team members, Liby Cielo, Meredith Stein, and Scott Campbell, reflecting the company's ongoing efforts to strengthen its commercial and clinical capabilities to support hospitals treating complex cardiorenal conditions.
- Market Expansion: Cielo will focus on hospital engagement and clinical education in South Texas, leveraging her experience in promoting Aquadex therapy across multiple hospital systems to further drive market acceptance of the therapy.
- Enhanced Clinical Education: Stein, with over 30 years of nursing experience and a history of establishing the Aquadex program, will bolster Nuwellis' clinical education capabilities in cardiovascular and critical care, improving patient treatment outcomes.
- Strengthened Sales Leadership: Campbell, as Area Vice President of Sales for the western U.S., will utilize his over 20 years of medical device experience to drive the adoption of Aquadex therapy in both adult and pediatric patients, particularly in emerging outpatient settings, aiding the company's further development in the healthcare market.
See More
Nuwellis Partners with CORE IR to Enhance Market Awareness
- Strategic Partnership: Nuwellis, Inc. has announced a partnership with CORE IR to enhance its visibility in the medical device and diagnostics market through an integrated communication strategy, effectively conveying its value proposition to attract investors and partners.
- Market Expansion Opportunities: Nuwellis CEO John Erb stated that CORE IR's expertise will assist the company in seizing significant market opportunities in the coming years, particularly in the cardiorenal solutions sector, thereby driving long-term value growth.
- Multi-Channel Communication Strategy: CORE IR will focus on utilizing public relations and digital communication services to convey Nuwellis' solutions, business model, and development plans to target audiences, thereby enhancing market awareness and expanding the company's influence.
- Team Expertise: CORE IR comprises a team with extensive market experience, specializing in providing investor relations and public relations services for small to mid-sized publicly traded and privately held companies, and is expected to support Nuwellis' communication goals through tailored strategies that facilitate ongoing market engagement.
See More
Nuwellis Establishes New Commercial Territory in South Texas
- Market Expansion Strategy: Nuwellis, Inc. has announced the establishment of a dedicated commercial territory in South Texas, aimed at strengthening collaborations with hospital systems and providing direct support for evaluating advanced fluid management strategies, particularly Aquadex therapy.
- Regional Healthcare Significance: South Texas is a significant healthcare region with large hospital systems and leading cardiac and critical care programs capable of managing complex fluid balance challenges, thereby enhancing Nuwellis' market influence.
- Enhanced Clinical Support: With the new territory, Nuwellis plans to offer more direct support to physicians and care teams, facilitating the evaluation and implementation of ultrafiltration therapy, which deepens partnerships with medical teams.
- Commercial Organization Strengthening: This expansion reflects Nuwellis' ongoing commitment to strengthening its commercial organization and supporting hospitals treating patients with complex cardiorenal conditions, thereby enhancing the company's competitiveness in the medical technology sector.
See More
Nuwellis Showcases New Research at International Heart and Lung Transplantation Conference
- Research Presentation: At the 2026 International Society for Heart and Lung Transplantation meeting, the University of Iowa showcased a case study on using ultrafiltration to treat pediatric heart failure, emphasizing its significance in managing complex pediatric cardiorenal patients, which may drive standardization in clinical practice.
- Clinical Application Potential: The case study demonstrated that Aquadex ultrafiltration therapy effectively managed fluid overload in patients with chemotherapy-induced dilated cardiomyopathy, improving pre-operative clinical status and enhancing post-transplant outcomes, indicating its potential in pediatric settings.
- Technology Promotion Strategy: Nuwellis CEO John Erb stated that the company will continue collaborating with practitioners to promote the adoption of Aquadex for pediatric indications, addressing fluid management challenges and enhancing patient care quality.
- Industry Exchange Platform: The ISHLT conference provided a vital opportunity for clinicians and researchers to share emerging data and engage in scientific dialogue, with Nuwellis' participation further solidifying its leadership position in heart and lung disease treatment.
See More
Nuwellis Receives Patent Allowance for Dual-Lumen Catheter
- Patent Progress: Nuwellis announced it received a Notice of Allowance from the USPTO for its dual-lumen catheter used in ultrafiltration therapy, aimed at improving blood flow and reducing treatment complications, which is expected to enhance its product lineup.
- Enhanced Design Flexibility: The catheter features an adjustable, flexible design that allows doctors to customize it during treatment, ensuring smoother usage and improved treatment outcomes across various patients.
- Market Expansion Potential: Once the patent is officially approved, it is anticipated to support Nuwellis in promoting ultrafiltration therapy in hospitals and outpatient settings, thereby expanding market share and enhancing competitive positioning.
- Stock Price Reaction: Despite the positive patent news, Nuwellis' stock is trading approximately 3% lower at around $1.13, reflecting market caution regarding its future growth potential.
See More
Nuwellis Announces Aquadex Software Update for Enhanced Clinical Workflow
- Software Update Enhancement: Nuwellis' release of the Aquadex SmartFlow® software update reduces ultrafiltration adjustment step size from 10 mL/hr to 5 mL/hr, which is particularly crucial in pediatric care, significantly improving clinical outcomes related to small-volume fluid shifts and enhancing patient safety and treatment efficacy.
- User Experience Optimization: The update aims to streamline clinical workflows and enhance device usability, especially providing better therapy visibility for nursing staff, which is expected to improve nursing efficiency and reduce operational errors, thereby elevating overall care quality.
- Key Algorithm Improvements: The update includes a refined blood flow algorithm designed to reduce nuisance alarms and improve flow stability, which will help clinicians detect potential filter clotting earlier, thus increasing the safety and effectiveness of treatments.
- No-Cost Update: This software update is available at no cost to existing customers and can be deployed through standard update processes, with support from Nuwellis' field and service teams ensuring a smooth transition to the new system, further solidifying customer relationships.
See More
Nuwellis Welcomes Back Three Key Team Members
- Team Restructuring: Nuwellis announces the return of three former team members, Liby Cielo, Meredith Stein, and Scott Campbell, reflecting the company's ongoing efforts to strengthen its commercial and clinical capabilities to support hospitals treating complex cardiorenal conditions.
- Market Expansion: Cielo will focus on hospital engagement and clinical education in South Texas, leveraging her experience in promoting Aquadex therapy across multiple hospital systems to further drive market acceptance of the therapy.
- Enhanced Clinical Education: Stein, with over 30 years of nursing experience and a history of establishing the Aquadex program, will bolster Nuwellis' clinical education capabilities in cardiovascular and critical care, improving patient treatment outcomes.
- Strengthened Sales Leadership: Campbell, as Area Vice President of Sales for the western U.S., will utilize his over 20 years of medical device experience to drive the adoption of Aquadex therapy in both adult and pediatric patients, particularly in emerging outpatient settings, aiding the company's further development in the healthcare market.
See More
Nuwellis Partners with CORE IR to Enhance Market Awareness
- Strategic Partnership: Nuwellis, Inc. has announced a partnership with CORE IR to enhance its visibility in the medical device and diagnostics market through an integrated communication strategy, effectively conveying its value proposition to attract investors and partners.
- Market Expansion Opportunities: Nuwellis CEO John Erb stated that CORE IR's expertise will assist the company in seizing significant market opportunities in the coming years, particularly in the cardiorenal solutions sector, thereby driving long-term value growth.
- Multi-Channel Communication Strategy: CORE IR will focus on utilizing public relations and digital communication services to convey Nuwellis' solutions, business model, and development plans to target audiences, thereby enhancing market awareness and expanding the company's influence.
- Team Expertise: CORE IR comprises a team with extensive market experience, specializing in providing investor relations and public relations services for small to mid-sized publicly traded and privately held companies, and is expected to support Nuwellis' communication goals through tailored strategies that facilitate ongoing market engagement.
See More
Nuwellis Establishes New Commercial Territory in South Texas
- Market Expansion Strategy: Nuwellis, Inc. has announced the establishment of a dedicated commercial territory in South Texas, aimed at strengthening collaborations with hospital systems and providing direct support for evaluating advanced fluid management strategies, particularly Aquadex therapy.
- Regional Healthcare Significance: South Texas is a significant healthcare region with large hospital systems and leading cardiac and critical care programs capable of managing complex fluid balance challenges, thereby enhancing Nuwellis' market influence.
- Enhanced Clinical Support: With the new territory, Nuwellis plans to offer more direct support to physicians and care teams, facilitating the evaluation and implementation of ultrafiltration therapy, which deepens partnerships with medical teams.
- Commercial Organization Strengthening: This expansion reflects Nuwellis' ongoing commitment to strengthening its commercial organization and supporting hospitals treating patients with complex cardiorenal conditions, thereby enhancing the company's competitiveness in the medical technology sector.
See More
